Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sensus Healthcare (SRTS) Cash & Equivalents (2016 - 2025)

Sensus Healthcare has reported Cash & Equivalents over the past 10 years, most recently at $22.1 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $22.1 million for Q4 2025, changed 0.12% from a year ago — trailing twelve months through Dec 2025 was $22.1 million (changed 0.12% YoY), and the annual figure for FY2025 was $22.1 million, changed 0.12%.
  • Cash & Equivalents for Q4 2025 was $22.1 million at Sensus Healthcare, down from $24.5 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for SRTS hit a ceiling of $37.6 million in Q3 2022 and a floor of $13.7 million in Q1 2021.
  • Median Cash & Equivalents over the past 5 years was $21.3 million (2023), compared with a mean of $21.9 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 140.48% in 2022 and later crashed 45.48% in 2023.
  • Sensus Healthcare's Cash & Equivalents stood at $14.5 million in 2021, then surged by 75.77% to $25.5 million in 2022, then fell by 9.29% to $23.1 million in 2023, then fell by 4.72% to $22.1 million in 2024, then grew by 0.12% to $22.1 million in 2025.
  • The last three reported values for Cash & Equivalents were $22.1 million (Q4 2025), $24.5 million (Q3 2025), and $22.2 million (Q2 2025) per Business Quant data.